Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–12. doi:10.3322/caac.21660. Epub 2021/02/05.
   PubMed Web of Science ®Google Scholar
• Pilipow K, Darwich A, Losurdo A. T-cell-based breast cancer Immunotherapy. Semin Cancer Biol. 2021;72:90–101. doi:10.1016/j.semcancer.2020.05.019. Epub 2020/06/04.
   PubMed Web of Science ®Google Scholar
• Debien V, De Caluwe A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7. doi:10.1038/s41523-023-00508-3. Epub 2023/02/14.
   PubMed Web of Science ®Google Scholar
• Cejuela M, Vethencourt A, Pernas S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. Curr Oncol Rep. 2022;24(12):1801–19. doi:10.1007/s11912-022-01339-4. Epub 2022/10/19.
   PubMed Web of Science ®Google Scholar
• Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, [email protected] EGCEa. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(12):1884–901. doi:10.1093/annonc/mdz411. Epub 2019/10/01.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):192–237. doi:10.1093/annonc/mdy275. Epub 2018/10/05.
   Google Scholar
• Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015;105(3):1809–31. doi:10.1007/s11192-015-1645-z. Epub 2015/11/26.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Samarasinghe G, Haddaway NR, Westgate MJ, O’Dea RE, Noble DWA, Lagisz M. Research weaving: visualizing the future of research synthesis. Trends Ecol Evol. 2019;34(3):224–38. doi:10.1016/j.tree.2018.11.007. Epub 2018/12/26.
   PubMed Web of Science ®Google Scholar
• Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge mapping of immunotherapy for hepatocellular carcinoma: a bibliometric study. Front Immunol. 2022;13:815575. doi:10.3389/fimmu.2022.815575. Epub 2022/02/18.
   PubMed Web of Science ®Google Scholar
• Ma L, Ma J, Teng M, Li Y. Visual analysis of colorectal cancer immunotherapy: a bibliometric analysis from 2012 to 2021. Front Immunol. 2022;13:843106. doi:10.3389/fimmu.2022.843106. Epub 2022/04/19.
   PubMed Web of Science ®Google Scholar
• Brandt JS, Hadaya O, Schuster M, Rosen T, Sauer MV, Ananth CV. A bibliometric analysis of top-cited journal articles in obstetrics and gynecology. JAMA Netw Open. 2019;2(12):e1918007. doi:10.1001/jamanetworkopen.2019.18007. Epub 2019/12/21.
   PubMed Web of Science ®Google Scholar
• Mongeon P, Paul-Hus A. The journal coverage of  Web of Science and Scopus: a comparative analysis. Scientometrics. 2016;106(1):213–28. doi:10.1007/s11192-015-1765-5.
   Web of Science ®Google Scholar
• Zhu JW, Liu WS. A tale of two databases: the use of Web of Science and Scopus in academic papers. Scientometrics. 2020;123(1):321–35. doi:10.1007/s11192-020-03387-8.
   Web of Science ®Google Scholar
• Merigo JM, Nunez A. Influential journals in health research: a bibliometric study. Global Health. 2016;12(1):46. doi:10.1186/s12992-016-0186-4. Epub 2016/08/24.
   PubMedGoogle Scholar
• Peng C, Kuang L, Zhao J, Ross AE, Wang Z, Ciolino JB. Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. J Control Release. 2022;345:625–45. doi:10.1016/j.jconrel.2022.03.031. Epub 2022/03/25.
   PubMed Web of Science ®Google Scholar
• Waltman L, van Raan AF, Smart S. Exploring the relationship between the engineering and physical sciences and the health and life sciences by advanced bibliometric methods. PLoS One. 2014;9(10):e111530. doi:10.1371/journal.pone.0111530. Epub 2014/11/02.
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. doi:10.1007/s11192-009-0146-3. Epub 2010/06/30.
   PubMed Web of Science ®Google Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 2004;101(Suppl 1):5303–10. doi:10.1073/pnas.0307513100. Epub 2004/01/16.
   PubMed Web of Science ®Google Scholar
• Chen CM, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Assoc Inf Sci Technol. 2014;65(2):334–51. doi:10.1002/asi.22968.
   Web of Science ®Google Scholar
• Kim MC, Nam S, Wang F, Zhu Y. Mapping scientific landscapes in UMLS research: a scientometric review. J Am Med Inform Assoc. 2020;27(10):1612–24. doi:10.1093/jamia/ocaa107. Epub 2020/10/16.
   PubMed Web of Science ®Google Scholar
• Okhovati M, Arshadi H. Covid-19 research progress: bibliometrics and visualization analysis. Med J Islam Repub Iran. 2021;35:20. doi:10.47176/mjiri.35.20. Epub 2021/05/18.
   PubMedGoogle Scholar
• Aria M, Cuccurullo C. Bibliometrix: an R-Tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959–75. doi:10.1016/j.joi.2017.08.007.
   Web of Science ®Google Scholar
• Cobo MJ, López-Herrera AG, Herrera-Viedma E, Herrera F. An approach for detecting, quantifying, and visualizing the evolution of a research field: a practical application to the fuzzy sets theory field. J Informetr. 2011;5:146–66. doi:10.1016/j.joi.2010.10.002.
   Web of Science ®Google Scholar
• Hirsch JE. Does the H index have predictive power? Proc Natl Acad Sci. 2007;104(49):19193–8. doi:10.1073/pnas.0707962104.
   PubMed Web of Science ®Google Scholar
• Egghe L. Theory and practise of the G-index. Scientometrics. 2006;69(1):131–52. doi:10.1007/s11192-006-0144-7.
   Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37. doi:10.1038/nm.3394. Epub 2013/11/10.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690. Epub 2012/06/05.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239. Epub 2012/03/23.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21. doi:10.1056/NEJMoa1809615. Epub 2018/10/23.
   PubMed Web of Science ®Google Scholar
• Jabbarzadeh Kaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, Wu X, Du F, Zhao Y, Shen J, et al. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – a comprehensive review from chemotherapy to immunotherapy. Pharmacol Res. 2020;156:104806. doi:10.1016/j.phrs.2020.104806. Epub 2020/04/16.
   PubMed Web of Science ®Google Scholar
• Nederlof I, Voorwerk L, Kok M. Facts and hopes in immunotherapy for early-stage triple-negative breast cancer. Clin Cancer Res. 2023;29(13):2362–70. doi:10.1158/1078-0432.CCR-22-0701. Epub 2023/01/10.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–28. doi:10.1016/S0140-6736(20)32531-9. Epub 2020/12/07.
   PubMed Web of Science ®Google Scholar
• Fu T, Dai LJ, Wu SY, Xiao Y, Ma D, Jiang YZ, Shao Z-M. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98. doi:10.1186/s13045-021-01103-4. Epub 2021/06/27.
   PubMed Web of Science ®Google Scholar
• Xu Y, Su GH, Ma D, Xiao Y, Shao ZM, Jiang YZ. Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. Signal Transduct Target Ther. 2021;6(1):312. doi:10.1038/s41392-021-00729-7. Epub 2021/08/22.
   PubMed Web of Science ®Google Scholar
• Wang R, Kumar P, Reda M, Wallstrum AG, Crumrine NA, Ngamcherdtrakul W, Yantasee W. Nanotechnology applications in breast cancer immunotherapy. Small. 2023:e2308639. doi:10.1002/smll.202308639. Epub 2023/12/21.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhu Y, Wang Z, Zhang T, Wu P, Huang J. Yin-Yang effect of tumor infiltrating B cells in breast cancer: from mechanism to immunotherapy. Cancer Lett. 2017;393:1–7. doi:10.1016/j.canlet.2017.02.008. Epub 2017/02/22.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184. doi:10.1186/s12943-022-01657-y. Epub 2022/09/27.
   PubMed Web of Science ®Google Scholar
• Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res. 2021;9(1):59. doi:10.1186/s40364-021-00312-w. Epub 2021/07/24.
   PubMed Web of Science ®Google Scholar
• Laszewicz W, Gabryelewicz A, Sipponen P, Kekki M, Laxen F, Siurala M. Gastric ulcer and gastritis: results of short-term follow-up examinations. Hepatogastroenterology. 1987;34(6):265–8. Epub 1987/12/01.
   PubMedGoogle Scholar
• Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, Brandt HJ, Kirkpatrick J, Rios P, Schamel WW, et al. Molecular mechanism of Shp2 activation by Pd-1 stimulation. Sci Adv. 2020;6(5):eaay4458. doi:10.1126/sciadv.aay4458. Epub 2020/02/18.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of Pd-1/Pd-L1 inhibitors. Mol Cancer. 2018;17(1):129. doi:10.1186/s12943-018-0864-3. Epub 2018/08/25.
   PubMed Web of Science ®Google Scholar
• Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362. doi:10.1038/s41392-021-00670-9. Epub 2021/10/09.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib keynote-012 study. J Clin Oncol. 2016;34(21):2460–7. doi:10.1200/JCO.2015.64.8931. Epub 2016/05/04.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II keynote-086 study. Ann Oncol. 2019;30(3):397–404. doi:10.1093/annonc/mdy517. Epub 2018/11/27.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132–40. doi:10.1001/jamaoncol.2019.1029. Epub 2019/06/14.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, Su S, Wang Q, Jin L, Wang Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020;8(1):e000696. doi:10.1136/jitc-2020-000696. Epub 2020/05/26.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi:10.1016/S1470-2045(17)30904-X. Epub 2017/12/14.
   PubMed Web of Science ®Google Scholar
• Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–69. doi:10.1200/JCO.18.01010. Epub 2019/01/17.
   PubMed Web of Science ®Google Scholar
• Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–89. doi:10.6004/jnccn.2020.7554. Epub 2020/04/08.
   PubMed Web of Science ®Google Scholar
• Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105. doi:10.1186/s12943-023-01805-y. Epub 2023/07/07.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al. Irecist: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):143–52. doi:10.1016/S1470-2045(17)30074-8. Epub 2017/03/09.
   PubMed Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, et al. A randomised phase ii study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of geparnuevo study. Ann Oncol. 2019;30(8):1279–88. doi:10.1093/annonc/mdz158. Epub 2019/05/17.
   PubMed Web of Science ®Google Scholar
• Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, Jank P, Sinn HP, Huober J, et al. Tumor mutational burden and immune infiltration as Independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in Geparnuevo. Ann Oncol. 2020;31(9):1216–22. doi:10.1016/j.annonc.2020.05.015. Epub 2020/05/29.
   PubMed Web of Science ®Google Scholar
• Singh VK, Singh P, Karmakar M, Leta J, Mayr P. The journal coverage of Web of Science, Scopus and Dimensions: a comparative analysis. Scientometrics. 2021;126(6):5113–42. doi:10.1007/s11192-021-03948-5.
   Web of Science ®Google Scholar
• Chen Y, Zhang X, Chen S, Zhang Y, Wang Y, Lu Q, Zhao Y. Bibliometric analysis of mental health during the COVID-19 pandemic. Asian J Psychiatr. 2021;65:102846. doi:10.1016/j.ajp.2021.102846. Epub 2021/09/26.
   PubMed Web of Science ®Google Scholar